Gene Molecular Alterations As Disease Prognostic Markers in Patients with Non-small Cell Lung Cancer (NSCLC)
Launched by HELLENIC COOPERATIVE ONCOLOGY GROUP · Mar 10, 2025
Trial Information
Current as of May 09, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Gene Molecular Alterations As Disease Prognostic Markers in Patients with Non-small Cell Lung Cancer (NSCLC)" is exploring the role of genetic changes in patients diagnosed with non-small cell lung cancer, which is a common type of lung cancer. Researchers want to understand how these genetic changes can help predict how the disease might progress over time. This study is based on a large group of patients who have been diagnosed with NSCLC over the past 20 years.
To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of non-small cell lung cancer. They also need to have enough available tissue sample for testing. However, patients with a history of other types of cancer, aside from certain very early-stage skin cancers or those who have been cancer-free for five years, are not eligible. Currently, the trial is active but not recruiting new participants. If you meet the criteria, you can expect that your genetic information will be analyzed to help researchers learn more about the disease and potentially improve future treatments for others with lung cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 and above
- • Histologically confirmed non-small cell lung cancer (NSCLC)
- • Adequate tissue availability for somatiic gene alteration testing
- • Suitable tissue for somatic gene alteration testing following
- Exclusion Criteria:
- • Unmet age eligibility inclusion criteria
- • Patients with personal medical history of malignancy, other than non-small cell lung cancer (NSCLC), with the exclusion of completely resected non-melanoma skin cancers, in situ carcinomas of the cervix uteri, in situ bladder carcinomas, in situ ductal breast carcinoma, and other cancers treated with curative intent with no evidence of disease recurrence for 5 years.
About Hellenic Cooperative Oncology Group
The Hellenic Cooperative Oncology Group (HeCOG) is a prominent clinical trial sponsor based in Greece, dedicated to advancing cancer research and improving patient outcomes through collaborative studies. Comprising a network of oncology professionals, HeCOG focuses on the design, implementation, and management of multicenter clinical trials that evaluate innovative treatment approaches and therapeutic strategies for various cancer types. With a commitment to fostering scientific excellence and enhancing the quality of cancer care, HeCOG actively engages in partnerships with academic institutions, pharmaceutical companies, and regulatory bodies to ensure the successful execution of its research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Athens, , Greece
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported